

FLOSStechRX

"Inspire Ingenuity, for the Future of Medicine and Medical Technology."



CONTENT

01 Company Overview

02 Business Model


03 Funding Needs

04 Demo & Business Traction

05 Founder's Journey

06 The Future





Focus on Dental Health Solutions



Preventative Health Innovations

Our solutions are designed to revolutionize dental health by utilizing advanced fiber floss technology and comprehensive microbial diagnostics, ensuring a proactive approach to gum disease and heart problem prevention.

Clinical Efficacy

Our fiber floss is clinically proven to eliminate up to 55% more plaque than traditional wax floss, significantly reducing the risk of pathogens entering the bloodstream and enhancing overall oral health.

Use of Fiber Floss Technology

Advanced Fiber Floss

Our innovative fiber floss is engineered to remove plaque more effectively than wax floss, promoting better oral hygiene and reducing the incidence of gum disease and other health complications.


Microbial Diagnostic Testing

We provide dentists with a stateof-the-art microbial diagnostic tool that helps identify and target specific pathogens, ensuring a more precise and effective treatment for patients.

Data Collection for R&D

Our system collects valuable data from each test, which is crucial for ongoing research and development, helping us to refine our products and develop new, more effective solutions.





Data Collection for R&D



Comprehensive Data Analysis

We gather and analyze extensive data from each patient, providing insights that drive innovation in dental care and contribute to the development of new, life-changing treatments.

Collaborative Research

Our data collection efforts are designed to foster collaboration with dental professionals and researchers, leading to a more comprehensive understanding of oral health and its impact on overall well-being.

Future-Forward Approach

By continuously collecting and analyzing data, we are paving the way for future advancements in dental technology and treatment, ensuring that our solutions remain at the forefront of the industry.





Revenue from Premium Cleanings

Premium Dental Microbial Diagnostic

This service includes a thorough dental cleaning using Fiber Floss, followed by a microbial diagnostic, generating significant revenue for dentists and contributing to our company's income.



Differentiated Pricing Tiers




Under 1000 tests weekly

Dentists charge \$200 per patient for premium cleanings, with revenue distribution among the dentist, laboratory, and FLOSStechRX at 50-50-50 ratio.


Over 1000 tests weekly

For higher volume, the revenue distribution shifts to 10-90-90, favoring the dentist, to incentivize higher usage and maximize profits.





Data collection for R&D We monetize by collecting data from cleanings, which is crucial for drug development, creating a mutually beneficial relationship with pharmaceutical companies. **Monetization Strategies High-margin operations** Our margins increase significantly once we surpass 1000 tests a week, allowing for higher profitability and reinvestment in the business. **Inventory and funding** We use funding to support board members and inventory, ensuring operational stability and growth potential as we scale.



Seeking \$5-10 million



Funding for board members

Required capital to support our board members for the next four years, ensuring strategic guidance and leadership in the growth of our dental preventative health company.

Inventory funding

To meet the increasing demand for our Fiber Floss and support our biotech solutions, inventory funding is crucial for maintaining product availability and service quality.

Capital for Board Members



Strategic leadership

The funding will enable our board members to provide strategic oversight, ensuring our company stays at the forefront of dental preventative health innovations.

Operational guidance


With additional capital, our board members can offer enhanced operational guidance, helping to navigate the complexities of scaling our business and expanding our market reach.



Inventory Funding Requirements

Product Availability

Ensuring a steady supply of Fiber Floss and other essential materials is critical to meeting customer demand and maintaining our reputation for quality and reliability.





Patient Interaction Process



Initial Consultation

The patient is greeted by the hygienist who offers a choice between a regular cleaning and a premium cleaning with a dental microbial diagnostic. This initial interaction is crucial for patient engagement and understanding the benefits of the premium service.

Consent and Data Collection

After choosing the premium cleaning, the patient fills out a consent form and answers 20 questions to collect essential data. This step ensures compliance and gathers valuable information for further analysis and research.

Pathogen Testing Protocol



Sample Collection

During the cleaning process, the hygienist uses fiber floss, which is clinically proven to eliminate 55% more plaque than wax floss. This sample is then collected and sent to the laboratory for pathogen testing.

Laboratory Analysis

The collected sample is tested for 4-5 pathogens in our state-of-theart laboratory. This analysis helps in identifying potential health risks and provides insights for personalized treatment plans.



Revenue Projections Per Partner

Under 1000 Tests Weekly

For dental practices conducting under 1000 tests a week, the revenue model includes the dentist charging \$200 for the premium cleaning, with the laboratory monetizing \$100 and FLOSStechRX monetizing \$50. This model ensures a balanced distribution of profits among all stakeholders.



Expansion Potential with Relationships




MB2 Dental Partnership

With relationships at MB2 Dental across 600 locations, the projected revenue is \$31.2 million annually, generating a profit of \$14 million. This partnership significantly boosts our market reach and revenue potential.

CRO and COO Networks

Our connections with CRO Russ Armburst, who has relationships with Pacific Dental Services at 1000 locations, and COO Jaret Z, who is connected with the Head of Periodontist at 5000 locations, offer extensive market access and potential for high revenue generation.



Experience in Medical Tech



Fiber Floss Development

Collaborated with Dr. Sharma to create the first LDT on Fiber Floss, testing for over 4-5 pathogens and significantly improving dental hygiene standards.

Biotech Innovations

Pioneered a biotech solution for dental microbial diagnostics, enhancing the ability of dentists to conduct premium cleanings and prevent heart and gum diseases.





Research and Development

Worked closely with Dr. Sharma and the laboratory team to develop and refine fiber floss technology, leading to a clinically proven 55% more plaque elimination compared to traditional wax floss.

Clinical Trials

Participated in extensive clinical trials to validate the efficacy of fiber floss in eliminating pathogens and reducing the risk of healthcare problems.

Data Collection

Implemented a system to gather crucial data from dental cleanings, aiding in the prevention of heart problems and gum disease while supporting future drug development.



Identified Market Gaps



Dental Practice Needs

Recognized the gap in dental practices' ability to conduct advanced microbial diagnostics and developed a solution to integrate this technology seamlessly into their operations.

Insurance Coverage

Identified the need for insurance coverage for premium cleanings with dental microbial diagnostics, aiming to make advanced dental care more accessible to patients.



Drug Development Support

Conducted extensive research and data collection to support drug development, addressing the critical need for new treatments in dental health and related medical conditions.



China has the highest cases of gum disease in the world! We plan to implement our biotech solution and conduct a better understanding of Oral Dental Health and utilize data for the future of medicine and medical technology for America!

Pharmaceutical giant looks to bring \$5.9 billion facility to Houston

Mike Damante

Damante May 21, 2025 1 ing to supply

So We're going to supply


So We're going to supply

A dental healthcare


our dental healthcare


data for this? It's in

data for this? right now!





Eli Lilly is looking to build an active pharmaceutical ingredient manufacturing facility at Generation Park. Rendering courtesy of McCord























\$3,166,792,200

This is an Important number. When we get into every dental office in America, then we're projected to reach this number. There's over 135,333 Dental Offices in America.

This has been calculated by only securing one test per location per year. This is caused by a 450% margin. Also, this has been calculated with our ad tech to promote a Premium Cleaning with a Dental Microbial Diagnostic.

We can license our technology to China to back for 30M capital



Dr. Sharma - Head of Laboratory Scientist.

I collaborated with Dr. Sharma with the testing needs for FLOSStechRX. He's an exceptional person with a high standard of science knowledge.

Jarret Zerb - COO.

Jarret is a high-quality individual in the works of Operations. He has relationships with the Head of Periodontist with over 5,000 Periodontist Dentists.

Chance Miller - Business Development Director.

Chance is an exquisite sales professional. He plays a key role in our operation as he helps Dentists with information by selling Dental Practices. He can bring us opportunity to help Dentists get into Research & Development.

Matthias Majerczyk - CFO

Matthias is a brilliant individual that has a dedication to numbers. He plays a key role in our operation by keeping our financials beautifully professional and firm.

Chris Dickey - VP of Product Development

I had the opportunity to work for Chris Dickey. He has over 25 years of manufacturing experience. He brings tremendous value to the organization by mentoring and working with engineers to produce a flawless product.

Dr. Murthy - Board Member

Doctor Murthy served as the President of Silicon Valley. He plays an important role as creating quantum computing applications and other applications that will arise from our collaboration development.

Dr. Fyffe - Head Scientist of Dental

Doctor Fyffe is a Dental Master. He has extensive knowledge and brings tremendous value to our organization

Russ Armburst - CRO

Russ has had a successful exit and has relationships to Delta Dental. He plays a dominate role for FLOSStechRX, given his experience of success and relationships

Travarse - CSO

Travarse is a gifted individual in strategy. He provides great value to the organization

Alec - CTO

Alec is a master of coding and can implement and fulfill technology of the future